263
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has invested more than €300 million ($325 million) into a new Bioprocessing Production Center in Daejeon, South Korea.
The large investment in Asia-Pacific demonstrates the company’s commitment to expanding its capacities in the fast-growing region. The investment is expected to create approximately 300 additional jobs by the end of 2028.
“The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA and gene…
The large investment in Asia-Pacific demonstrates the company’s commitment to expanding its capacities in the fast-growing region. The investment is expected to create approximately 300 additional jobs by the end of 2028.
“The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA and gene…